tlr4 blocking antibodies Search Results


tlr4 antibody blocking peptide  (Bio-Techne corporation)
90
Bio-Techne corporation tlr4 antibody blocking peptide
Tlr4 Antibody Blocking Peptide, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr4+blocking+antibodies/bio-techne+corporation___nbp2-24821pep?v=Bio-Techne+corporation
Average 90 stars, based on 1 article reviews
tlr4 antibody blocking peptide - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
tlr4 blocking antibodies  (Novus Biologicals)
90
Novus Biologicals tlr4 blocking antibodies
( A ) MDMs were treated with TLR2 agonist (Pam3CSK4, 1 µg/ml), <t>TLR4</t> agonist (MPLA, 1 µg/ml) and TLR9 agonist (ODN2006, 10 µg/ml) for 9 h. As a control, MDMs were also treated with γ- Mtb H37Rv (10 µg/ml). Cell surface TF activity was determined in factor X activation assay.* indicates significant difference compared to untreated cells (P≤0.01); # denotes significant difference compared to γ- Mtb treated cells (P<0.01) ( B ) MDMs were preincubated with CD14, TLR2 and TLR4 blocking antibodies (each, 10 µg/ml) either alone or in combination and with isotype control IgG for 45 min at 37°C and then cells were stimulated with γ- Mtb for 9 h. At the end of the stimulation period cell surface TF activity was measured in factor X activation assay. # denotes significant inhibition compared to γ- Mtb or LPS alone treated cells (P<0.05); paired t-test. Data are mean ± SEM (n = 3–8).
Tlr4 Blocking Antibodies, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr4+blocking+antibodies/pmc03454383-157-2-7?v=Novus+Biologicals
Average 90 stars, based on 1 article reviews
tlr4 blocking antibodies - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
10 g/ml tlr4 blocking ab  (Bionova Inc)
90
Bionova Inc 10 g/ml tlr4 blocking ab
( A ) MDMs were treated with TLR2 agonist (Pam3CSK4, 1 µg/ml), <t>TLR4</t> agonist (MPLA, 1 µg/ml) and TLR9 agonist (ODN2006, 10 µg/ml) for 9 h. As a control, MDMs were also treated with γ- Mtb H37Rv (10 µg/ml). Cell surface TF activity was determined in factor X activation assay.* indicates significant difference compared to untreated cells (P≤0.01); # denotes significant difference compared to γ- Mtb treated cells (P<0.01) ( B ) MDMs were preincubated with CD14, TLR2 and TLR4 blocking antibodies (each, 10 µg/ml) either alone or in combination and with isotype control IgG for 45 min at 37°C and then cells were stimulated with γ- Mtb for 9 h. At the end of the stimulation period cell surface TF activity was measured in factor X activation assay. # denotes significant inhibition compared to γ- Mtb or LPS alone treated cells (P<0.05); paired t-test. Data are mean ± SEM (n = 3–8).
10 G/Ml Tlr4 Blocking Ab, supplied by Bionova Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tlr4+blocking+antibodies/pm18061674-54-7-13?v=Bionova+Inc
Average 90 stars, based on 1 article reviews
10 g/ml tlr4 blocking ab - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
tlr4 antibody blocking peptide  (Novus Biologicals)
N/A
TLR4 Antibody Blocking Peptide
   Buy from Supplier
m tlr4 antibody n term blocking peptide  (Abcepta)
N/A
   Buy from Supplier
tlr4 antibody center blocking peptide  (Abcepta)
N/A
   Buy from Supplier
mouse tlr4 antibody c term blocking peptide  (Abcepta)
N/A
   Buy from Supplier

Image Search Results


( A ) MDMs were treated with TLR2 agonist (Pam3CSK4, 1 µg/ml), TLR4 agonist (MPLA, 1 µg/ml) and TLR9 agonist (ODN2006, 10 µg/ml) for 9 h. As a control, MDMs were also treated with γ- Mtb H37Rv (10 µg/ml). Cell surface TF activity was determined in factor X activation assay.* indicates significant difference compared to untreated cells (P≤0.01); # denotes significant difference compared to γ- Mtb treated cells (P<0.01) ( B ) MDMs were preincubated with CD14, TLR2 and TLR4 blocking antibodies (each, 10 µg/ml) either alone or in combination and with isotype control IgG for 45 min at 37°C and then cells were stimulated with γ- Mtb for 9 h. At the end of the stimulation period cell surface TF activity was measured in factor X activation assay. # denotes significant inhibition compared to γ- Mtb or LPS alone treated cells (P<0.05); paired t-test. Data are mean ± SEM (n = 3–8).

Journal: PLoS ONE

Article Title: Mycobacterium tuberculosis Infection and Tissue Factor Expression in Macrophages

doi: 10.1371/journal.pone.0045700

Figure Lengend Snippet: ( A ) MDMs were treated with TLR2 agonist (Pam3CSK4, 1 µg/ml), TLR4 agonist (MPLA, 1 µg/ml) and TLR9 agonist (ODN2006, 10 µg/ml) for 9 h. As a control, MDMs were also treated with γ- Mtb H37Rv (10 µg/ml). Cell surface TF activity was determined in factor X activation assay.* indicates significant difference compared to untreated cells (P≤0.01); # denotes significant difference compared to γ- Mtb treated cells (P<0.01) ( B ) MDMs were preincubated with CD14, TLR2 and TLR4 blocking antibodies (each, 10 µg/ml) either alone or in combination and with isotype control IgG for 45 min at 37°C and then cells were stimulated with γ- Mtb for 9 h. At the end of the stimulation period cell surface TF activity was measured in factor X activation assay. # denotes significant inhibition compared to γ- Mtb or LPS alone treated cells (P<0.05); paired t-test. Data are mean ± SEM (n = 3–8).

Article Snippet: TLR2 and TLR4 blocking antibodies were from Imgenex Corp. (San Diego, CA).

Techniques: Control, Activity Assay, Activation Assay, Blocking Assay, Inhibition